Correlation Between Puma Biotechnology and Editas Medicine

Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Editas Medicine at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Editas Medicine into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Puma Biotechnology and Editas Medicine, you can compare the effects of market volatilities on Puma Biotechnology and Editas Medicine and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Editas Medicine. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Editas Medicine.

Diversification Opportunities for Puma Biotechnology and Editas Medicine

0.05

Correlation Coefficient

Puma Biotechnology  Editas Medicine

Significant diversification

The 3 months correlation between Puma and Editas is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Editas Medicine in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Editas Medicine and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Editas Medicine. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Editas Medicine has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Editas Medicine go up and down completely randomly.

Pair Corralation between Puma Biotechnology and Editas Medicine

Given the investment horizon of 90 days Puma Biotechnology is expected to generate 5.94 times less return on investment than Editas Medicine. But when comparing it to its historical volatility, Puma Biotechnology is 2.78 times less risky than Editas Medicine. It trades about 0.03 of its potential returns per unit of risk. Editas Medicine is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  121.00  in Editas Medicine on December 27, 2024 and sell it today you would earn a total of  6.00  from holding Editas Medicine or generate 4.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Puma Biotechnology  vs.  Editas Medicine

Puma Biotechnology

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Editas Medicine

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Editas Medicine are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating forward indicators, Editas Medicine unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Puma Biotechnology and Editas Medicine

The main advantage of trading using opposite Puma Biotechnology and Editas Medicine positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Editas Medicine can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will offset losses from the drop in Editas Medicine's long position.

The idea behind Puma Biotechnology and Editas Medicine pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.